|
市場調查報告書
成為下一波一鳴驚人藥物的新一代治療用抗體的尋求
Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs
|
成為下一波一鳴驚人藥物的新一代治療用抗體的尋求 是由出版商Decision Resources, Inc.在2011年06月所出版的。
這份英文市場調查報告書價格從美金4600起跳。
新一代抗體不僅僅是現有的蛋白質治療藥物的同類產品也是透過蛋白質工程所產生的產品。由於單株抗體和抗體的治療藥物的成功，成為讓對製藥公司開發新的暢銷藥物以及致力於具有優勢的新一代抗體開發的契機。
本報告提供治療用抗體市場收益，傳統的單株抗體的優點，先導物最適化，新一代抗體今後的預測等彙整資料，為您概述為以下內容。
摘要整理
簡介
抗體片段和變異
免疫球蛋白G(IgG)抗體的一般的特性
- Fab 片段
- 單鏈可變區片段
- 單域抗體
- FC融合蛋白質
多效價，多特定，多模塊抗體
抗體模擬物
T細胞受體治療藥物
先導物最適化
新一代抗體今後的預測
圖表
Abstract
Introduction:
Next-generation antibodies promise to create not just me-too products of
existing protein therapeutics but me-better products through protein
engineering. The success of monoclonal antibody (MAb) and antibody-derived
therapeutics is encouraging pharmaceutical companies to explore exciting,
next-generation antibody formats with superior properties as sources of
blockbuster drugs. Formats of interest include antibody fragments, Fc fusion
proteins, bispecific antibodies, multimodular antibodies, antibody mimetics,
and T-cell receptors. These formats could yield drugs against difficult
targets and enable companies to bypass existing patents. The first wave of
next-generation antibodies has reached the market, and many more novel drugs
are in development.
Questions Answered in This Report:
- The number of therapeutic antibodies and antibody derivatives approved by
regulatory agencies has risen dramatically in recent years. Which
antibody-based therapies are among the top-selling drugs worldwide? How much
revenue do these drugs generate?
- The commercial success of therapeutic antibodies and antibody derivatives
is encouraging pharmaceutical companies to explore novel antibody formats as
the next source of blockbuster drugs. Which formats are most interesting
to pharmaceutical companies? Which technologies hold the most promise of
generating innovative drug classes? What drugs based on novel formats have
already reached the market?
- The current market landscape offers innovative biotech companies with
novel development programs significant commercial opportunities for generating
next-generation antibodies. What companies are developing novel formats
for creating innovative, antibody-based therapeutics? What technologies are
these companies developing? How far have these programs advanced?
- Pharmaceutical companies can gain access to new technologies and antibody
candidates through partnerships and M&As. Which pharmaceutical companies
have formed major alliances with or acquired biotech companies? Which novel
strategies are attracting the interest of Big Pharma?
- Lead optimization and manufacture of next-generation antibody formats
present significant challenges. What obstacles hinder the optimization and
manufacture of next-generation antibody therapeutics? Which companies have
developed technologies to overcome these difficulties?
Scope:
- Landscape: Rise of therapeutic antibodies, revenue generated,
advantages of traditional monoclonal antibodies (MAbs), novel approaches and
formats, main challenges
- Antibody fragments and variants: Fab fragments, single-chain
variable region fragments (scFv), single-domain antibodies (dAb), Fc fusion
proteins, development candidates
- Bispecific, multivalent, and multimodular antibodies: Advantages,
myriad formats, manufacturing challenges, development candidates
- Antibody mimetics: Technological approaches, structures,
development candidates
- T-cell receptor therapeutics: T-cell receptors, major
histocompatibility complex, cell-mediated immunity, development candidates
- Lead optimization: Challenges, manufacturing issues, promising
technologies and approaches
- Therapeutic areas: Broadly applicable platform useful for targeting
multiple therapeutic areas; current therapies approved for a wide range of
diseases, including cancers, autoimmune diseases, inflammatory disorders,
infectious diseases, and ocular disorders
- Detailed figures: Detailed schematics of various antibody and
antibody derivative structures
- Outlook for next-generation antibodies: Promising classes and
mechanisms, applications of small antibody fragments, lead optimization,
strategic advantages of biotech companies.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Antibody Fragments and Variants
- General Features of Immunoglobulin G (IgG) Antibody
- Fab Fragments
- Single-Chain Variable Region Fragments (scFv)
- Single-Domain Antibodies (dAbs)
- Fc Fusion Proteins
- Multivalent, Multispecific, and Multimodular Antibodies
- Multivalent and Multispecific Antibodies
- Multimodular Antibodies
- Antibody Mimetics
- T-Cell Receptor Therapeutics
- Lead Optimization
- Outlook for Next-Generation Antibodies
Tables
- 1. Categories of Next-Generation Antibodies and Antibody Derivatives
- 2. Select Companies with Next-Generation Antibody Technology
Figures
- 1. Sales and Approval Trends for Therapeutic Antibodies and
Antibody Derivatives
- 2. Antibody Fragments and Marketed Products
- 3. Single-Chain Antibody Fragments
- 4. Comparison of Human, Rodent, Camelid, and Shark Antibody
Structures
- 5. Fc Fusion Proteins and Marketed Products
- 6. Multivalent and Multispecific Antibody Structures
- 7. Mechanism of Action of Trifunctional Bispecific Antibody Removab
- 8. Multimodular Antibody Formats
- 9. Fynomer Antibody Mimetic Structure
- 10. T-Cell Receptor Therapeutics
- 11. Display Technologies for Lead Identification and Optimization
of Protein Therapeutics
- A. General Features of Immunoglobulin G (IgG) Antibody
|
